Holen Sie sich die Stockscreener-App
0.9246
2.38%
-0.0231
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
RNXTRenovoRx Inc Latest SEC Filings - Finviz
RenovoRx Receives Nasdaq Delisting Notice: Key Details from Latest 8-K Filing - Minichart
RenovoRx Received Notice of Noncompliance - TradingView
RenovoRx Stockholders Approve Directors and Equity Plan - The Globe and Mail
Nasdaq grants RenovoRx (RNXT) new deadline to fix $1 bid price - Stock Titan
RenovoRx, Inc. Financial Disclosures & SEC Filings - TradingView
RenovoRx 2021 Omnibus Equity Incentive Plan Amended: Key Vote Results and SEC Filing Details (June 2026) - Minichart
RenovoRx (RNXT) investors approve directors, expand equity plan and ratify 2026 auditor - Stock Titan
Enterprise value to revenue forward of RenovoRx, Inc. – NASDAQ:RNXT - TradingView
Price to book forward of RenovoRx, Inc. – NASDAQ:RNXT - TradingView
RNXT Forecast — Price Target — Prediction for 2027 - TradingView
RenovoRx Inc (RNXT) Valuation: PE, PB & Fair Value Analysis - TradingKey
RenovoRx, Inc. Actuals & Estimates (NASDAQ:RNXT) - TradingView
Form 4 RenovoRx Inc For: 24 June By Investing.com - Investing.com Nigeria
RenovoRx (RNXT) director reorganizes indirect share holdings via trust - Stock Titan
RNXT: Strong commercial growth and clinical data position the therapy for major impact in cancer care - TradingView
RNXT: Strong commercial growth and clinical data position the platform for expanded cancer therapy adoption - TradingView
RenovoRx (RNXT) Stock Price, News & Analysis - MarketBeat
RenovoRx, Inc. (RNXT) reports Q1 loss, tops revenue estimates - MSN
RenovoRx Inc (RNXT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RenovoRx Inc (RNXT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RenovoRx Inc (RNXT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RenovoRx Inc (RNXT) Institutional Confidence - TradingKey
RenovoRx Inc (RNXT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RenovoRx Inc (RNXT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RenovoRx Inc (RNXT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre‑Revenue Biotech Advances Clinical ProgramsAnalyst Consensus Shift - newsline.com
RNXT News | RENOVORX INC (NASDAQ:RNXT) - ChartMill
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP in Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer - The Manila Times
Targeted artery chemo saw 52% tumor activity drop in pancreatic cancer case - Stock Titan
RenovoRx (RNXT) Q1 2026 Earnings: EPS Falls Short of Estimates as Pre-Revenue Biotech Advances Clinical PipelineGuidance Update - newsline.com
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Oncology Firm Advances Clinical PipelineEarnings Whisper Number - newsline.com
RenovoRx Inc. (RNXT) Holds Steady Near Support as Investors Eye ResistanceInstitutional Flow Picks - newsline.com
RNXT Q1 2026 Earnings: EPS Miss Widens Losses as Stock Declines 10.6%Post-Earnings Drift - newsline.com
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd - Investing News Network
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Clinical PipelinePre-Announcement Alert - newsline.com
Stock Ratings | Raymond James raised its target price for Micron (MU) to $1,100; Ascendiant raised its target price for RenovoRx (RNXT) to $14, indicating a potential upside of 1,420.58% - Sahm
RNXT Maintains Buy Rating by Ascendiant Capital -- Price Target Raised to $14.00 - GuruFocus
RenovoRx Inc. (RNXT) Q1 2026 Earnings: Loss per share misses estimates as stock declinesEBITDA Estimate Trend - dars.gov.et
New chemotherapy delivery method scores FDA orphan drug status - Rare Cancer News
RNXT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances TrialsEarnings Preview - The Legal Advocate
RenovoRx Inc. (RNXT) Moves Higher by 6.2% as Shares Approach Resistance at $1.04Volatility Term Structure - The Legal Advocate
RenovoRx (RNXT) Advances 6.2% as Momentum Builds Toward ResistanceCall Spread Alert - The Legal Advocate
RenovoRx receives FDA orphan drug designation for oxaliplatin - Investing.com UK
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer - Investing News Network
RenovoRx receives FDA orphan drug designation for oxaliplatin By Investing.com - Investing.com Australia
RenovoRx gets FDA orphan drug designation for oxaliplatin to treat pancreatic cancer - marketscreener.com
RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer - TradingView
FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer - Stock Titan
RenovoRxTiger-Pac Trial Enrollment to Clos - Moomoo
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting - Investing News Network
1.83%
3.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):